Continue reading this on our app for a better experience

Open in App
Floating Button
Home News Company in the news

TalkMed receives 'interest' from unnamed 'persons' 'considering' shares purchase

The Edge Singapore
The Edge Singapore  • 1 min read
TalkMed receives 'interest' from unnamed 'persons' 'considering' shares purchase
The company is now trading at around 15x historical earnings
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

TalkMed Group says that it has received "interest" from "persons" who are considering the acquisition of a stake in the company. 

"The discussions are preliminary at this stage and there is no assurance that a transaction will take place," says the company on April 6.

TalkMed, a specialist cancer medical group, is controlled by group CEO Dr Ang Peng Tiam, who has an interest in 64.74% of the shares. Group COO Dr Khoo Kei Siong holds another 7.49%.

On Feb 20, the company reported earnings of $32.7 million for FY2023, up 9.7% over the preceding year ended Dec 31 2022. Revenue in the same period was up 9.4% to $83.8 million, due to higher patient numbers.

Despite the better earnings, Talkmed is paying a lower dividend of 1.3 cents for FY2023, down from 1.5 cents paid for FY2022.

TalkMed was listed back in 2014, with its IPO shares offered at 20 cents each. It surged to an all-time high of 89 cents in 2017.

See also: A*STAR, Flagship Pioneering jointly commit up to US$100 mil to spur biotech innovation in S’pore, APAC

TalkMed shares closed at 38 cents on April 5 and with FY2023 EPS of 2.43 cents, values the company at 15.6x historical earnings.

 

 

 

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.